Company news
Insmed Incorporated (NASDAQ:INSM) news
Insmed Incorporated news releases on 6ix. Latest, Oct 5, 2026: Insmed Announces CFO Transition
Press releases & updates
Insmed Announces CFO Transition
October 4, 2026
Insmed Announces CFO Transition
October 5, 2026
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
September 21, 2026
Insmed Expands Community Impact During Fifth Annual Global Day of Good
September 16, 2026
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
September 3, 2026
Insmed to Present at September 2026 Investor Conferences
August 26, 2026
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
August 24, 2026
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
July 23, 2026
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
July 16, 2026
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
June 23, 2026
Insmed Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
June 5, 2026
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
May 27, 2026
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
May 6, 2026
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
May 4, 2026
Insmed to Present at May 2026 Investor Conferences
April 30, 2026
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
April 23, 2026
Insmed Provides Clinical Update on Phase 2b CEDAR Study
April 7, 2026
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
March 22, 2026
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
February 19, 2026
Insmed To Present at March 2026 Investor Conferences
February 13, 2026
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
February 5, 2026
Definium Therapeutics Appoints Roger Adsett to Board of Directors
January 29, 2026
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
January 27, 2026
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
January 1, 2026
Insmed Provides Clinical and Business Update
December 16, 2025
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 3, 2025
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
November 17, 2025
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
November 12, 2025
Insmed To Present at November and December 2025 Investor Conferences
November 4, 2025
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
October 29, 2025
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
October 22, 2025
CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
October 16, 2025
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
October 15, 2025
Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
October 14, 2025
Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
September 21, 2025
Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight
August 25, 2025
Insmed To Present at September Investor Conferences
August 20, 2025
VytlOne Announces New Partnership with Insmed
August 13, 2025
PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
August 13, 2025
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
August 11, 2025
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
July 23, 2025
Insmed Announces Proposed $650 Million Public Offering of Common Stock
June 10, 2025
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
June 10, 2025
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
June 9, 2025
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
May 27, 2025
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study
May 20, 2025